Scienmag

JUNE 28, 2022

AMES, IA – Through CRISPR and other gene-editing technologies, researchers and developers are poised to bring dozens – if not hundreds – of new products to grocery stores: mushrooms with longer shelf lives, drought-resistant corn and bananas impervious to a fungus threatening the global supply.

Gene Editing 88

Gene Editing Gene Production Development 88

Pharmaceutical Technology

MARCH 28, 2023

Under the terms of the deal, the company will receive non-exclusive rights to CRISPR/Cas9, a gene-editing technology of CRISPR Therapeutics, for the development of potentially curative T1D cell therapies. The gene-editing technology allows for precise, directed changes to genomic DNA.

Gene Editing 235

Gene Editing Gene DNA Gene Therapy 235

Scienmag

NOVEMBER 8, 2021

Credit: John Innes Centre A gene which has profound effects on the production of seeds has been identified by researchers from the John Innes Centre. Gene-editing techniques helped to identify and explain the key gene, ZIP4, in wheat which is responsible for maintaining 50% of yield in this global crop.

Gene Editing 85

Gene Editing Gene Production Research 85

Pharmaceutical Technology

NOVEMBER 16, 2022

Under the deal, the LentiPeak lentiviral vector technology platform and cell therapy production expertise of ElevateBio BaseCamp will be used by Affini-T to develop its investigational oncogenic driver programmes in the clinic. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Development 246

Development Gene Therapy Engineer Gene Editing 246

Worldwide Clinical Trials

OCTOBER 24, 2023

Global Genes is a rare disease umbrella organization dedicated to eliminating the burdens and challenges of rare diseases for patients and families globally. Although no two rare disease patient communities are identical, there are common themes to the evolutionary arc of PAO maturation.

Gene 130

Gene Gene Editing Gene Therapy Clinical Trials 130

BioSpace

NOVEMBER 15, 2023

s Medicines and Healthcare products Regulatory Agency on Thursday provided conditional marketing authorization for Vertex Pharmaceuticals and CRISPR Therapeutics’ gene-edited therapy exa-cel.

Gene Editing 120

Gene Editing Gene Medicine Production 120

pharmaphorum

JUNE 12, 2022

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical trial, with an update at the EHA congress showing long-term effects on the symptoms of both beta thalassaemia and sickle cell disease. billion product if it gets approved for both indications. .

Gene Editing 59

Gene Editing Gene Gene Therapy Drugs 59

Scienmag

JANUARY 12, 2021

Martins Scientists have used gene-editing advances to achieve a tenfold increase in the production of super-bug targeting formicamycin antibiotics. Credit: Dr Dino J. Discovered within the last ten years, formicamycins have great […].

Gene Editing 53

Gene Editing Gene Bacteria Scientist 53

Fierce Pharma

NOVEMBER 27, 2023

The gene-editing therapy won a world-first approval in the U.K. earlier this month.

Gene Editing 100

Gene Editing Gene Manufacturing Production 100

BioTech 365

JUNE 21, 2021

QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments QIAprep&amp CRISPR Kit and Q-Primer Solutions expand QIAGEN portfolio for CRISPR applications Products are … Continue reading → (..)

Gene Editing 40

Gene Editing Gene Production 40

pharmaphorum

OCTOBER 21, 2020

million) to develop its gene therapy for a rare ocular disease. SPVN06 is a proprietary, mutation-agnostic, AAV gene therapy consisting of one neurotrophic factor and one oxidative stress reducing enzyme which, acting together, aim to slow or stop the degeneration of photoreceptors. French biotech SparingVision has raised 44.5

Gene Therapy 98

Gene Therapy Gene Gene Editing Genetics 98

Pharmaceutical Technology

AUGUST 26, 2022

ElevateBio has signed a long-term strategic collaboration with the University of Pittsburgh, US, to establish a biomanufacturing centre for expediting cell and gene therapy development. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 162

Gene Therapy Gene Editing Gene Manufacturing 162

Scienmag

NOVEMBER 9, 2020

Their approach […].

Gene Editing 97

Gene Editing Gene Production Research 97

Scienmag

NOVEMBER 19, 2020

Media contacts: Jennifer Kuzma, jkuzma@ncsu.edu Khara Grieger, kdgriege@ncsu.edu Mick Kulikowski, News Services, 919.218.5937 or mick_kulikowski@ncsu.edu Researchers at North Carolina State University call for a coalition of biotech industry, government and non-government organizations, trade organizations, and academic experts to work together to (..)

Gene Editing 44

Gene Editing Gene Research Production 44

BioTech 365

JANUARY 18, 2021

EdiGene Announces Approval of its IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in ?-thalassemia

Gene Editing 40

Gene Editing Gene Production 40

pharmaphorum

JUNE 28, 2021

The reductions matched the efficacy of current therapies for ATTR amyloidosis that require chronic dosing such as Alnylam’s Onpattro (patisiran) and Ionis/Akcea’s Tegsedi (inotersen) – both gene-silencing agents which can cost around $450,000 a year. — Eric Topol (@EricTopol) June 26, 2021.

In-Vivo 105

In-Vivo Gene Editing Trials Drugs 105

pharmaphorum

SEPTEMBER 29, 2020

As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies. These benefits strengthen capabilities and accelerate product development, ultimately producing higher quality and more effective therapies.

Research 132

Research Gene Editing Development Gene 132

Pharmaceutical Technology

FEBRUARY 23, 2023

It covers a broad range of techniques from the less invasive practice of intermittent fasting to drastic and invasive procedures, such as the implanting of microchips or injecting of gene-editing enzymes. As a broader concept, biohacking encourages experimental biotechnology outside the confines of traditional research environments.

Gene Editing 278

Gene Editing Regulation Production Nurses 278

Pharmaceutical Technology

JANUARY 19, 2023

GlobalData’s Pharma Intelligence Center shows 19 autologous CAR-T cell products in Phase I, and nine products in Phase II, globally. None of these products are in a registrational trial, and as such, GlobalData does not anticipate their entry into the AML market earlier than 2028.

Marketing 130

Marketing Gene Editing Production Sales 130

pharmaphorum

MAY 7, 2021

Gene editing firm CRISPR Therapeutics has announced a collaboration with US biotech Nkarta to develop natural killer (NK) cell therapies for cancer. It’s at the forefront of gene editing although the technology has spawned rivals including Intellia Therapeutics, Caribou Biosciences, Sangamo Therapeutics and Mammoth Biosciences.

Gene Editing 52

Gene Editing Gene Genetic Engineering DNA 52

pharmaphorum

DECEMBER 6, 2020

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta thalassaemia and sickle cell disease in an early-stage trial reported at the American Society of Haematology (ASH) annual meeting.

Gene Editing 52

Gene Editing Gene In-Vivo Genetics 52

XTalks

NOVEMBER 3, 2023

After spending almost an entire day deliberating the safety of Vertex Pharmaceuticals’ and CRISPR Therapeutics’ CRISPR-based gene therapy exa-cel for sickle cell disease, a US Food and Drug Administration (FDA) advisory panel appears to be satisfied with what it saw. CRISPR works as genetic scissors to edit parts of the genome.

Gene Therapy 59

Gene Therapy Gene Gene Editing In-Vivo 59

pharmaphorum

SEPTEMBER 14, 2022

SparingVision has raised €75 million in second-round funding that will be used to fund clinical trials of gene therapies for ocular diseases retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD). The post SparingVision raises €75m for eye disease gene therapies appeared first on.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Editing 52

Pharmaceutical Technology

MARCH 9, 2023

T-cell activation can be measured by assessing proliferation, up-regulation of activation markers and production of effector cytokines (IFN-gamma and TNF-alpha). Activation of T-cell proliferation specifically in a tumour is crucial for reducing the autoimmune side effects of antitumour immunotherapy.

In-Vitro 130

In-Vitro Gene Editing Medicine Licensing 130

Advarra

NOVEMBER 29, 2022

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. Recent Problems in Cell and Gene Therapy Development. Dealing with confusing regulatory guidelines is one of the top obstacles researchers face as they develop CGT products 1.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

Pharmaceutical Technology

MARCH 2, 2023

The research using ImmunoGen’s technology will enable the discovery of the agents for use with gene editing. ImmunoGen has announced an agreement granting rights to Vertex Pharmaceuticals to carry out research using antibody-drug conjugate (ADC) technology for the discovery of new targeted conditioning agents.

Gene Editing 130

Gene Editing Gene Development Research 130

Pharmaceutical Technology

MARCH 1, 2023

Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

XTalks

MAY 22, 2023

Pairwise , a startup based in Durham, North Carolina, has launched its first CRISPR-developed product in the US: Conscious Greens. Touted as a mix of superfood leafy greens, the product claims to offer twice the nutrition of traditional romaine lettuce and comes with an appealing fresh flavor.

Branding 98

Branding Gene Editing DNA Production 98

BioTech 365

OCTOBER 26, 2020

.–(BUSINESS WIRE)–EdiGene, Inc. ( “Company”, or “EdiGene”), today announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has accepted for review the Company’s Investigational New Drug (IND) application for ET-01, autologous CD34+ … Continue reading → (..)

Gene Editing 40

Gene Editing Production Gene Drugs 40

The Pharma Data

NOVEMBER 30, 2020

Vivlion holds an exclusive license to Goethe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries. It will be exciting to see Vivlion combine its expertise with the power of CRISPR gene editing to facilitate the Company’s entry into the global CRISPR/Cas tool market.”.

Genomics 52

Genomics Genome Licensing Licensing 52

Roots Analysis

FEBRUARY 27, 2024

The global genome editing market is anticipated to grow at a CAGR of 12.6% How is the genome editing market landscape evolving: Currently, there is an evident increase in demand for complex biological therapies (including regenerative medicine products), which has created an urgent need for robust genome editing techniques.

Genome 40

Genome Genomics Gene In-Vivo 40

pharmaphorum

APRIL 25, 2022

This forum will unite the exclusive community advancing the production of high-quality and consistent iPSC products, with in depth case studies aimed to develop optimal differentiation, cryopreservation, and analytical protocol to enhance process development to ensure it is robust, rapid and repeatable. Hear from: Fate Therapeutics.

Manufacturing 52

Manufacturing Gene Editing Branding Production 52

The Pharma Data

NOVEMBER 22, 2020

Scientists in Israel have used the CRISPR Cas-9 gene editing system to destroy cancerous cells in mice without damaging other cells. The product is the most advanced gene-editing approach in development for transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease. ” Source link.

Gene Editing 52

Gene Editing DNA Genomics Genome 52

XTalks

SEPTEMBER 20, 2024

Vittoria Biotherapeutics is a clinical-stage cell therapy company that incorporates the latest advancements in cell therapy and gene editing with a unique approach that potentially overcomes some of the issues with this therapeutic modality. Its therapeutic pipeline targets unmet needs in oncology and autoimmune disease.

Gene Editing 52

Gene Editing Manufacturing Gene In-Vivo 52

The Pharma Data

JANUARY 19, 2021

A naturally occurring system for tuning CRISPR-Cas9 expressing in bacteria, identified in a study published in Cell , could have implications for gene editing therapies as well. A CRISPR-Cas9 system has two components: the Cas9 guide RNA that directs the system to edit a particular gene, and the CRISPR “scissors” that make the cut.

Bacteria 52

Bacteria Gene Editing Research RNA 52